C hronic liver diseases can progress to severe fibrosis and cirrhosis. Fibrosis stage is associated with several complications, such as portal hypertension, variceal bleeding, hepatic encephalopathy, and liver failure (1,2). Liver cirrhosis is also a risk factor of hepatocellular carcinoma (3). Because studies have revealed that liver fibrosis can be reversible (4-6), its detection at an early stage and correct staging are essential for improving prognosis.Liver biopsy is the reference standard for diagnosing parenchymal liver diseases (7). Besides procedural risks (eg, bleeding and infection) and patient discomfort, sampling error from biopsy may occur because of small sample size, an inhomogeneous distribution of disease, and observer variability (8). Several imaging techniques, especially MRI performed with liver-specific contrast agents or functional methods such as MR elastography and diffusion-weighted (DW) imaging, have been reported as markers of liver fibrosis (9-11). MR elastography helps to provide liver fibrosis staging with sensitivity and specificity values up to 90%-99% (12-16) by measuring tissue elasticity by using mechanical waves. However, MR elastography may not be available in many institutions because of the need for complex mechanical setup, dedicated MRI sequence, and lengthy image acquisition.DW imaging helps to measure the diffusion-driven displacement of water protons, which are more hindered in fibrotic tissue. The standard method based on an apparent diffusion coefficient (ADC) has been evaluated in